Cambio de paradigma en el EGFR mutado: desde las primeras mutaciones a las de resistencia - page 15

3rd generation EGFR-TKIs, osimertinib

Osimertinib, Phase I

Osimertinib, Phase II

RR: 61%. PFS 9.6 mo.

T790M-, RR 21%, PFS 2.8 mo

N=253

RR: 70%. PFS: 9.9 mo

N=210

(40% brain M1)

Jänne, NEJM 2015; Goss, Lancet Oncol 2016

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,5,6,7,8,9,10,11,12,13,14 16,17,18,19,20,21,22,23,24,25,...35